Pierre Beaurang's Insider Trades & SAST Disclosures
Pierre Beaurang's most recent trade in Nurix Therapeutics Inc was a trade of 7,500 Common Stock done at an average price of $1.1 . Disclosure was reported to the exchange on Aug. 10, 2021.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Pierre Beaurang.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 10 Aug 2021 | 7,500 | 11,830 | - | 1.1 | 8,325 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 7,500 | 6,562 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 29.74 per share. | 10 Aug 2021 | 5,620 | 6,210 | - | 29.7 | 167,129 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.21 per share. | 10 Aug 2021 | 1,880 | 4,330 | - | 30.2 | 56,797 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 7,500 | 14,062 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 12 Jul 2021 | 7,500 | 11,830 | - | 1.1 | 8,325 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 23.88 per share. | 12 Jul 2021 | 7,100 | 4,730 | - | 23.9 | 169,527 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 24.73 per share. | 12 Jul 2021 | 400 | 4,330 | - | 24.7 | 9,892 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 10 Jun 2021 | 7,500 | 11,830 | - | 1.1 | 8,325 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2021 | 7,500 | 21,562 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 29.15 per share. | 10 Jun 2021 | 6,000 | 5,830 | - | 29.1 | 174,881 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.01 per share. | 10 Jun 2021 | 1,100 | 4,730 | - | 30.0 | 33,006 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.90 per share. | 10 Jun 2021 | 400 | 4,330 | - | 30.9 | 12,361 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 10 May 2021 | 7,500 | 11,830 | - | 1.1 | 8,325 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 7,500 | 29,062 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 26.07 per share. | 10 May 2021 | 4,299 | 7,531 | - | 26.1 | 112,068 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 26.87 per share. | 10 May 2021 | 2,501 | 5,030 | - | 26.9 | 67,213 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 27.66 per share. | 10 May 2021 | 700 | 4,330 | - | 27.7 | 19,363 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 12 Apr 2021 | 5,104 | 11,830 | - | 1.1 | 5,665 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 5,104 | 36,562 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 26.83 per share. | 12 Apr 2021 | 4,072 | 7,758 | - | 26.8 | 109,245 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 27.67 per share. | 12 Apr 2021 | 2,883 | 4,875 | - | 27.7 | 79,770 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 12 Apr 2021 | 2,396 | 6,726 | - | 0.8 | 2,013 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 2,396 | 0 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 28.66 per share. | 12 Apr 2021 | 545 | 4,330 | - | 28.7 | 15,617 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 25 Mar 2021 | 4,330 | 4,330 | - | 0.8 | 3,637 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 4,330 | 2,396 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2021 | 7,500 | 6,726 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 08 Mar 2021 | 7,500 | 7,500 | - | 0.8 | 6,300 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 37.31 per share. | 08 Mar 2021 | 4,490 | 200 | - | 37.3 | 167,504 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 36.48 per share. | 08 Mar 2021 | 2,810 | 4,690 | - | 36.5 | 102,507 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 38.34 per share. | 08 Mar 2021 | 200 | 0 | - | 38.3 | 7,668 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 9,107 | 14,226 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 18 Feb 2021 | 9,107 | 9,107 | - | 0.8 | 7,650 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 35.99 per share. | 18 Feb 2021 | 6,400 | 1,400 | - | 36.0 | 230,328 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 35.02 per share. | 18 Feb 2021 | 4,553 | 7,800 | - | 35.0 | 159,454 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 3,797 | 72,869 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.26 per share. | 18 Feb 2021 | 3,797 | 12,904 | - | 7.3 | 27,566 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 34.19 per share. | 18 Feb 2021 | 2,647 | 12,353 | - | 34.2 | 90,496 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 2,096 | 14,678 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.57 per share. | 18 Feb 2021 | 2,096 | 15,000 | - | 9.6 | 20,059 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 36.92 per share. | 18 Feb 2021 | 1,000 | 400 | - | 36.9 | 36,924 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 37.88 per share. | 18 Feb 2021 | 400 | 0 | - | 37.9 | 15,150 | Common Stock |
| Nurix Therapeutics Inc | Pierre Beaurang | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges